The Alinity m HR HPV assay is approved for HPV detection and for regular cervical cancer screening. Credit: Shameer Pk from Pixabay.

The US Food and Drug Administration (FDA) has approved Abbott’s molecular human papillomavirus (HPV) screening solution, an addition to the Alinity m diagnostic assay family.

The screening solution tool is designed to detect high-risk HPV infections that are said to be common in most sexually active adults, according to the US Centers for Disease Control.

Abbott said there are several variants of the HPV, distinguished by their distinct genetic signatures or genotypes.

Certain HPV genotypes have the potential to cause cancer, particularly cervical cancer in females.

Traditionally, Pap tests were employed for cervical cancer screening. However, current professional guidelines advocate for primary screening via HPV infection tests as the superior method for detecting cervical cancer over Pap testing.

See Also:

As per professional medical guidelines, the Alinity m high risk (HR) HPV assay is approved for HPV detection and regular cervical cancer screening.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The assay is also authorised for co-testing, in conjunction with a Pap test, for those patients and physicians who opt for both tests.

The Alinity m HR HPV assay will provide data on five risk categories, encompassing the 14 different potentially cancer-causing genotypes of the virus.

This would assist physicians in not only detecting the presence of an HPV infection but also determining whether the infection stems from one or more of the types that might lead to cancer.

Abbott molecular business vice-president Keith Cienkus said: “HPV testing is a powerful tool for detecting HPV infections that can lead to certain cancers, including cervical cancer and illustrates the power of molecular diagnostics in infectious disease.”

The Abbott Alinity m HR HPV assay is planned to be made available for use on Abbott’s Alinity m laboratory instrument.

The assays that will be made available for use on the Alinity m system in the US include Resp-4-Plex, SARS-CoV-2, HCV (Hepatitis C), HIV-1 (Human Immunodeficiency Virus type 1), HBV (Hepatitis B), STI (CT/NG/TV/MG), CMV (Cytomegalovirus) and EBV (Epstein–Barr virus).